Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

Next Previous
Trial Profile

Congenital Muscular Dystrophy Ascending Multiple Dose Cohort Study Analyzing Pharmacokinetics at Three Dose Levels In Children and Adolescents With Assessment of Safety and Tolerability of Omigapil (CALLISTO)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Omigapil (Primary)
  • Indications Congenital disorders; Muscular dystrophies
  • Focus Pharmacokinetics
  • Acronyms CALLISTO
  • Sponsors Santhera Pharmaceuticals

Most Recent Events

  • 05 Apr 2018 According to a Santhera Pharmaceuticals media release, the preparation and conduct of this CALLISTO trial was supported financially by a public-private partnership including two patient organizations, the US-based Cure CMD and the Swiss Foundation for Research on Muscle Diseases (FRSMM), EndoStem, an EU 7th Framework program, and NIH clinical resources.
  • 05 Apr 2018 According to a Santhera Pharmaceuticals media release, the company will share detailed data from the CALLISTO trial at upcoming scientific conferences and with the patient community.
  • 05 Apr 2018 Primary endpoint has been met. (To establish the pharmacokinetic profile of omigapil at a range of doses in paediatric and adolescent patients with CMD)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top